Skip to main content

Table 1 Characteristics of included studies

From: Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock – a systematic review and meta-analysis

Study

Annane et al. 2013[26]

Bouadma et al. 2010[27]

Hochreiter et al. 2009[28]

Jensen et al. 2011[29]

Nobre et al. 2008[30]

Schroeder et al. 2009[31]

Svoboda et al. 2007[32]

Design

RCT

RCT

RCT

RCT

RCT

RCT

RCT

Setting

Surgical and medical ICU

Surgical and medical ICU

Surgical ICU

Surgical and medical ICU

Surgical and medical ICU

Surgical ICU

Surgical ICU

Condition

Severe sepsis and septic shock

Septic shock

Severe sepsis

Severe sepsis and septic shock

Severe sepsis and septic shock

Severe sepsis

Severe sepsis

Total number of included patients

61

267

110

459

79

27

72

Number of patients

       

PCT group/control group

31/30

138/129 (septic shock)

57/53

247/212

39/40

14/13

38/34

55/53 (positive blood culture)

Hospital mortality

       

Relative risk (95% CI)

0.68 (0.30; 1.55)

NA

1.00 (0.53; 1.86)

NA

1.03 (0.46; 2.31)

0.93 (0.23; 3.81)

NA

Events PCT group/events control group

7/10

15/14

9/9

3/3

28-day mortality

       

Relative risk (95% CI)

NA

1.15 (0.81; 1.63)

NA

1.02 (0.80; 1.30)

1.03 (0.43; 2.46)

NA

0.69 (0.35; 1.36)

Events PCT group/events control group

48/39 (septic shock)

90/76

8/8

10/13

Duration of antibiotic treatment, days

       

PCT group/control group

5/5 (median)

9.8/12.8 (mean) (only positive blood culture)

5.9/7.9 (mean)

NA

6.0/9.5 (median)

6.6/8.3 (mean)

NA

Length of ICU stay, days

       

PCT group/control group

22/23 (median)

NA

15.5/17.7 (mean)

6.0/5.0 (median)

4.0/7.0 (median)

16.4/16.7 (mean)

16.1/19.4 (mean)

Length of hospital stay, days

       

PCT group/control group

27/33 (median)

NA

NA

23.0/22.0 (median)

17.0/23.5 (median)

NA

NA

SOFA score

       

PCT group/control group

9.5/10 (median)

NA

6.7/7.0 (mean)

NA

6.4/6.6 (mean)

7.3/8.3 (mean)

7.9/9.3 (mean)

8.5 to 11/8 to 11 (IQR)

3.68/3.62 (SD)

3.3/3.0 (SD)

3.5/4.2 (SD)

2.8/3.3 (SD)

Medical patients, %*

97%

89%

0%

59%

NA

0%

0%

Subgroup of study

No

Yes

No

Yes

No

No

No

Duration of study, months

36

12

15

29

15

7

29

Study protocol available

Yes

Yes

Yes

Yes

Yes

No

No

Country

France

France

Germany

Denmark

Switzerland

Germany

Czech Republic

  1. PCT, procalcitonin; RCT, randomized controlled clinical trial; SOFA, sequential organ failure assessment; NA, data were not available; *data were stated in study or calculated from information given in study.